Brokers Set Expectations for Sensus Healthcare, Inc.'s Q2 2024 Earnings (NASDAQ:SRTS)

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - HC Wainwright issued their Q2 2024 earnings per share estimates for Sensus Healthcare in a research note issued to investors on Monday, May 13th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of $0.02 for the quarter. HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for Sensus Healthcare's FY2024 earnings at $0.29 EPS.

Separately, Maxim Group increased their price target on shares of Sensus Healthcare from $7.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, May 10th.

Sensus Healthcare Price Performance

NASDAQ:SRTS traded up $0.84 during trading hours on Wednesday, reaching $6.14. The company had a trading volume of 878,800 shares, compared to its average volume of 397,651. Sensus Healthcare has a 1-year low of $1.79 and a 1-year high of $6.20. The business's 50 day moving average price is $3.71 and its 200-day moving average price is $3.20. The firm has a market cap of $100.63 million, a PE ratio of 21.17 and a beta of 0.92.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.18. The business had revenue of $10.66 million during the quarter, compared to analysts' expectations of $4.33 million. Sensus Healthcare had a return on equity of 9.76% and a net margin of 14.70%. During the same quarter in the previous year, the firm posted ($0.12) EPS.

Institutional Investors Weigh In On Sensus Healthcare

Large investors have recently modified their holdings of the company. Hillsdale Investment Management Inc. acquired a new position in Sensus Healthcare in the first quarter valued at approximately $155,000. Creekmur Asset Management LLC acquired a new stake in shares of Sensus Healthcare during the 4th quarter valued at approximately $83,000. Sachetta LLC purchased a new position in shares of Sensus Healthcare in the fourth quarter valued at $247,000. Finally, Perritt Capital Management Inc. increased its holdings in Sensus Healthcare by 5.0% during the 3rd quarter. Perritt Capital Management Inc. now owns 105,586 shares of the company's stock valued at $292,000 after acquiring an additional 5,000 shares in the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.